Cell Recognition & the Immune System (AQA A-Level Biology): Revision Notes

Vaccination

Understanding immunity

Immunity refers to an organism's capacity to resist infection. This protection operates through two distinct mechanisms that differ in their source and duration.

Passive immunity occurs when antibodies are introduced from an external source rather than being produced by the individual's own immune system. This form of protection is immediate but temporary. Since the recipient does not manufacture these antibodies, no memory cells are formed when the antibodies break down.

Active immunity develops when an individual's immune system produces its own antibodies following exposure to a pathogen or its antigens. This process takes time to establish but provides longer-lasting protection. Active immunity occurs in two ways:

• Natural active immunity results from infection with a disease-causing organism under normal circumstances, leading to antibody production that may persist for years
• Artificial active immunity forms the foundation of vaccination programmes, where immune responses are deliberately triggered without causing disease symptoms

The vaccination process

Vaccination involves introducing specific disease antigens into the body through injection or oral administration. The material used is called a vaccine and contains one or more antigenic components derived from the target pathogen.

When administered, vaccines stimulate immune responses similar to those described in previous topics on cell recognition. The immune system responds to these foreign antigens, but because only small quantities are introduced, the response is initially mild. The critical outcome is the production of memory cells that remain in circulation.

These memory cells enable rapid, enhanced immune responses when the same pathogen is encountered again. This secondary response produces antibodies quickly and in large quantities, typically eliminating the infection before symptoms develop or become severe.

Large-scale vaccination programmes provide protection not only for individuals but for entire populations through collective immunity effects.

Requirements for effective vaccination programmes

Successful vaccination initiatives depend on several interconnected factors that must align for optimal disease prevention.

• Economic and logistical considerations include ensuring adequate vaccine supplies are available at reasonable cost to reach most vulnerable populations. The production, storage and transportation infrastructure must support the vaccine's requirements, often involving sophisticated refrigeration systems and sterile handling procedures.
• Safety profiles matter significantly because adverse reactions may discourage public participation. Programmes require minimal side-effects to maintain community confidence and uptake rates.
• Administrative capacity involves training healthcare personnel to deliver vaccines properly and at appropriate times across multiple locations. This includes establishing vaccination centres and ensuring staff possess relevant skills for different population groups.
• Population coverage must be sufficient to establish protective community-level effects. This requires reaching the vast majority of vulnerable individuals to generate herd immunity.

Herd immunity

Herd immunity develops when vaccination rates within a population reach levels that make pathogen transmission difficult. The concept relies on limiting contact between susceptible individuals and infectious agents.

When most people possess immunity to a disease, unvaccinated individuals gain indirect protection. Pathogens struggle to find new hosts in highly immunised populations, reducing transmission chains and protecting those who cannot be vaccinated.

This protection mechanism proves essential because universal vaccination remains impossible. Babies, young children, and immunocompromised individuals often cannot receive certain vaccines safely. The percentage of people requiring vaccination for herd immunity varies between diseases, but achieving this threshold protects the entire community.

For herd immunity to work effectively, vaccination campaigns should occur within concentrated time periods rather than being spread over many years. This approach minimises the window during which pathogens can circulate and establish transmission patterns.

Limitations of vaccination programmes

Even well-designed vaccination programmes may fail to eliminate diseases entirely due to several biological and practical constraints.

• Individual immune system variations mean some people do not develop adequate immunity following vaccination. Those with compromised immune systems may produce insufficient antibody responses, leaving them vulnerable despite receiving vaccines.
• Timing issues can occur when individuals contract diseases shortly after vaccination but before immunity fully develops. These people may harbour pathogens and potentially infect others during this vulnerable period.

• Pathogen evolution presents ongoing challenges, particularly with organisms that undergo frequent antigenic variability. When pathogens mutate rapidly, their surface antigens change faster than vaccine development can keep pace. The influenza virus exemplifies this problem, requiring annual vaccine updates as viral strains evolve continuously.
• Pathogen diversity complicates vaccine development for organisms with numerous variants. Some pathogens exist in over 100 different forms, making comprehensive vaccine coverage nearly impossible.
• Pathogen behaviour allows some organisms to evade immune detection by hiding within cells or colonising areas with limited immune surveillance, such as the intestinal tract.
• Social factors influence programme success when individuals refuse vaccination for religious, ethical, or medical reasons. Unfounded concerns about vaccine safety can reduce uptake rates below levels needed for herd immunity.

Ethical considerations

Vaccination programmes raise complex ethical questions that balance individual rights against collective health benefits.

• Risk assessment requires weighing potential vaccine side-effects against disease risks. While vaccines generally carry minimal risks, some individuals may experience adverse reactions. Society must decide how to balance these individual risks against the broader population benefits of disease prevention.
• Research ethics involve questions about animal testing in vaccine development and the acceptable limits of human trials, particularly in regions where targeted diseases are common.
• Individual autonomy concerns arise around mandatory vaccination policies. Different societies approach the balance between personal choice and public health requirements differently, with ongoing debates about when compulsory vaccination may be justified.
• Resource allocation decisions involve determining whether expensive vaccination programmes should continue after diseases become rare, potentially redirecting resources from other health priorities.
• Testing protocols raise questions about acceptable research methods, informed consent procedures, and the extent to which individuals should accept personal risks for collective benefit.

Case study: MMR vaccine controversy

This controversy demonstrates how scientific evidence requires careful evaluation and peer review. Public understanding of research limitations proves crucial for making informed decisions about vaccination programmes.

The episode illustrates broader challenges in science communication, showing how initial findings may be misinterpreted before more comprehensive evidence becomes available.